• Pharvaris is developing oral treatments for hereditary angioedema (HAE), leveraging its bradykinin B2 antagonist franchise.
• Morgan Stanley set a price target of $41 for PHVS, indicating a potential increase of approximately 39.62%.
• The company's strong phase 2 results and high probability of phase 3 success have led to a buy rating and a target price of $40.

Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE). The company is gaining attention due to its innovative approach with its bradykinin B2 antagonist franchise. This unique treatment method is designed to address both on-demand and preventive needs for HAE patients.

On December 3, 2025, Maxwell Skor from Morgan Stanley set a price target of $41 for PHVS. At that time, the stock was priced at $29.37, suggesting a potential increase of approximately 39.62%. This optimistic outlook aligns with the company's promising late-stage pipeline and the anticipated phase 3 data by the end of 2025.

Pharvaris has been initiated with a buy rating and a target price of $40, driven by its strong phase 2 results and regulatory precedents. The mechanism of Deucrictibant, a key component of their treatment, has been validated, significantly reducing the risk for the upcoming phase 3 readout. The probability of success for this phase is estimated at over 90%.

Currently, PHVS is priced at $29.37, marking a 21.75% increase, or $5.25, from the previous session. The stock has fluctuated between $23.80 and $29.68 today. Over the past year, it has seen a high of $29.67 and a low of $11.51, reflecting its volatile nature.

Pharvaris has a market capitalization of approximately $1.91 billion, indicating its substantial presence in the biopharmaceutical sector. With a trading volume of 3,539,819 shares on the NASDAQ today, investor interest in PHVS remains strong, driven by its promising pipeline and potential market impact.